Approach to the management of rare clinical presentations of macroprolactinomas in reproductive-aged women  by Espinosa De Ycaza, Ana et al.
Case Reports in Women's Health 8 (2015) 9–12
Contents lists available at ScienceDirect
Case Reports in Women's Health
j ourna l homepage: www.e lsev ie r .com/ locate /c rwhApproach to the management of rare clinical presentations of
macroprolactinomas in reproductive-aged womenAna Espinosa De Ycaza a,⁎, Alice Y. Chang b, Jani R. Jensen c, Zaraq Khan d, Dana Erickson e
a Division of Endocrinology, Diabetes, Metabolism, and Nutrition, 200 First Street SW, Mayo Clinic, Rochester, MN, 55905, United States
b Division of Endocrinology, Diabetes, Metabolism, and Nutrition, 200 First Street SW, Mayo Clinic, Rochester, MN, 55905 United States
c Division of Reproductive Endocrinology and Infertility, 200 First Street SW, Mayo Clinic, Rochester, MN, 55905, United States
d Division of Reproductive Endocrinology and Infertility, 200 First Street SW, Mayo Clinic, Rochester, MN, 55905, United States
e Division of Endocrinology, Diabetes, Metabolism, and Nutrition, 200 First Street SW, Mayo Clinic, Rochester, MN, 55905, United StatesAbbreviations: MRI, magnetic resonance imaging; D
Insulin-like growth factor-1.
⁎ Corresponding author.
E-mail addresses: espinosadeycaza.ana@mayo.edu (A.
chang.alice1@mayo.edu (A.Y. Chang), jensen.jani@mayo.e
khan.zaraq@mayo.edu (Z. Khan), erickson.dana@mayo.ed
http://dx.doi.org/10.1016/j.crwh.2015.09.001
2214-9112/© 2015 The Authors. Published by Elsevier B.Va b s t r a c ta r t i c l e i n f oArticle history:
Received 29 August 2015
Received in revised form 7 September 2015
Accepted 16 September 2015





United StatesObjective: To describe 2 cases of macroprolactinomas with atypical presentation in women desiring pregnancy
that illustrate important considerations in the management approach for macroprolactinomas in reproductive-
aged women.
Patient(s): Case 1was a 26-year-oldwoman referred to our institution for possible tumor resection after pituitary
apoplexy during her ﬁrst pregnancy. Instead, she underwent treatment with cabergoline for a year with goals of
normalization of prolactin and decrease in tumor size to b1 cm before trying to conceive. Case 2 was an 18-year-
old woman with a macroprolactinoma intolerant to dopamine agonists. She underwent stereotactic radiosur-
gery, with marked reduction in tumor size and normalization of prolactin levels. She conceived and delivered
a healthy infant 3 years after radiosurgery.
Conclusion:Management of macroprolactinomas inwomen desiring pregnancy requires careful consideration of
alternatives to surgery which could impair pituitary function and fertility and awareness of treatment goals that
canminimize the risks for pituitary apoplexy and vision loss during pregnancy. It is important to increase aware-
ness of these options prior to initiation of treatment and conception.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Hyperprolactinemia due to prolactinoma is an important and treat-
able cause of infertility in women [1]. Most prolactinomas are
microadenomas (lesions b1 cm) and may be associated with galactor-
rhea, amenorrhea, and infertility. In contrast, macroprolactinomas
(lesions ≥1 cm) have the potential of causing progressive mass effects,
including visual ﬁeld defects, headaches, or development of hypopitu-
itarism. When considering treatment of macroprolactinomas in
reproductive-age women, clinicians must not only consider restoration
of fertility, they must also be aware of potential complications during
pregnancy, including vision loss, pituitary apoplexy, and effects of ther-
apy on the fetus. These considerations highlight the need to be vigilant
about the duration of medical therapy and treatment goals prior to try-




. This is an open access article underthe patient and care providers to minimize the risk for complications
during pregnancy. For women intolerant or resistant to medications, al-
ternatives to surgical resection of macroadenomas must be carefully
considered because of the risk for impaired pituitary function after
surgery.
We report 2 challenging cases ofmacroprolactinomas in reproductive-
aged women to illustrate the decision-making process. We also include a
review of the relevant literature describing management approaches.
2. Cases
2.1. Case 1
A 26-year old G0womanwith a history of a macroprolactinomawas
referred for possible surgical resection of the tumor. She reported eight
years of oligomenorrhea, with six to nine menstrual cycles per year. At
age 23, she was found to have a prolactin level of 14,869 pmol/l
(normal: 130–1174 pmol/l) during a work-up for infertility. Pituitary
magnetic resonance imaging (MRI) revealed a 1.9 cm× 1.3 cmpituitary
mass consistentwith an adenoma. Thyroid function tests, serumcortisol
and IGF-1 levels were normal. The patient was initiated on oral contra-
ceptives and bromocriptine (2.5 mg, twice daily) which decreased herthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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strated no change in tumor size at 6months. Because symptoms of nau-
sea and dizziness limited her compliance with bromocriptine, she was
switched to cabergoline (0.25 mg, twice weekly). After three months
of cabergoline, prolactin decreased further to 174 pmol/l and the
tumor decreased slightly in size to 1.9 cm × 0.8 cm. The patient missed
one reﬁll of oral contraceptives and became pregnant 1 month later.
Dopamine agonist (DA) therapy was discontinued when the pregnancy
was conﬁrmed.
During the third trimester, at 28 weeks gestation, the patient pre-
sented with an acute onset of severe headache. MRI showed apoplexy
into the tumor, which increased in size to 1.4 × 2.0 × 1.2 cm, with evi-
dence of right cavernous sinus invasion (Fig. 1A–C). Visual ﬁeld testing
was normal. She started glucocorticoid replacement therapy because of
low random cortisol levels (96.6 nmol/l) and concern for secondary ad-
renal insufﬁciency. Cabergolinewas reinitiated at 0.25mg twiceweekly.
The remainder of her pregnancy was uneventful; she delivered a full-
term, 3.1-kg healthy baby via vaginal delivery with vacuum assistance.
Postpartum, DA therapy was changed back to bromocriptine and
oral contraceptives were restarted. One week after delivery, the tumor
had slightly increased to 1.4 × 2.4 × 1.4 cm. After 6 months of bromo-
criptine, her prolactin level was 1304 pmol/l and repeat imaging
showed a decrease in size (1.1 × 1.4 × 1.0 cm)with persistent right cav-
ernous sinus invasion. Repeat imaging another 6 months later showed
no change in size. She was able to taper off hydrocortisone within a
year of delivery.
With no signiﬁcant change in size of the tumor on DA therapy, she
was referred to our institution for consideration of surgery to reduce
the risk of pituitary apoplexy in a subsequent desired pregnancy. With
the cavernous sinus invasion decreasing the chance for surgical cure
and considering the risks of pituitary injury and impaired fertility, we
recommended that she switch to cabergoline therapy for a year with
the goal of stabilizing the adenoma and reducing its size to b1 cmbefore
trying to conceive again. With cabergoline, her prolactin decreased fur-
ther to 478 pmol/l. After additional 10 months of cabergoline therapy,
MRI showed the tumor had decreased to b1 cm, and her prolactin
remained at 522 pmol/l. She discontinued oral contraceptives andFig. 1.Magnetic resonance images. Figure parts A–C correspond to Case 1; parts D–E correspon
right cavernous sinus invasion (white arrow indicates pituitary tumor, gray arrow indicates ri
shows apoplexy (white arrow indicates intratumoral hemorrhage). C, T1 coronal image with g
ﬁrst pregnancy with persistent right cavernous sinus invasion. D, T1 coronal image with gad
which corresponded to a 1.1-cm macroprolactinoma (gray arrow indicates normal pituitary
left cavernous sinus (white arrow).became pregnant 4 months later. Her pregnancy has been uneventful
through the third trimester of pregnancy. Prolactin levels were not
closely monitored during her second pregnancy as they are not reliable
throughout gestation. The levels can signiﬁcantly increase with preg-
nancy per se.
2.2. Case 2
An 18-year-old G0 woman presented with a 4-year history of galac-
torrhea and an 8-month history of secondary amenorrhea. Her prolactin
level was 7174 pmol/l (reference, 130–1174 pmol/l). Thyroid function
tests, serum cortisol and IGF-1 levels were normal. A brain MRI showed
a normal-appearing sella with an asymmetric, hypoenhancing 1.1 cm
soft-tissue mass in the left cavernous sinus, consistent with a pituitary
adenoma (Fig. 1D–E). Medical therapy was attempted with both bro-
mocriptine and subsequently cabergoline but the patient developed
nausea and severe fatigue with both medications. She also reported
side effects to oral contraceptive pills. Given her symptoms, intolerance
to dopamine agonists, and tumor location in the cavernous sinus,
gamma knife radiosurgery was recommended. She underwent stereo-
tactic radiosurgery with 50 Gy as themaximal dose and 25 Gy adminis-
tered to the margins of the tumor without complications. A repeat MRI
1 year after radiosurgery showed signiﬁcant involution of the mass in
the left cavernous sinus. Her prolactin levels over the 2-year period
after radiosurgery progressively decreased from 7174 to 1304 pmol/l.
Pituitary function remained intact. The galactorrhea resolved,menstrual
periods resumed, and she was able to spontaneously conceive 3 years
after radiosurgery; she delivered a full-term, 3.5-kg healthy baby via
vaginal delivery. Six years after radiosurgery, her prolactin levels contin-
ue to be normal (435 pmol/l), with normal pituitary function, and the
child has normal development.
3. Discussion
These cases illustrate the decision-making process involved when
considering therapeutic options for macroprolactinomas before, during,d to Case 2. A, T1 coronal image with gadolinium shows a pituitary macroadenoma with
ght cavernous sinus invasion). B, T1 coronal image without gadolinium during pregnancy
adolinium shows reduced tumor size after dopamine agonist therapy 6 months after her
olinium shows an asymmetric soft-tissue area in the left cavernous sinus (white arrow),
tissue). E, fast spin-echo image 4 years after radiosurgery shows tumor involution in the
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discuss include:
3.1. What are the Treatment Goals for Macroprolactinomas Before
Conception?
For a reproductive-age woman with a macroprolactinoma who de-
sires fertility, preconception treatment must consider risk reduction
for tumor complications during pregnancy, along with the goal of
restoring andmaintaining fertility and ovarian function. Dopamine ago-
nists are the ﬁrst recommended treatment formost prolactin-producing
macroadenomas [2]. Bromocriptine has the larger safety database (6239
pregnancies vs 789 for cabergoline) [3]; thus, bromocriptine is typically
recommended as the initial treatment. However, no increase in fetal
anomalies has been reported with cabergoline exposure in the ﬁrst tri-
mester. The optimal duration of DA therapy before conception thatmin-
imizes pregnancy risk is not known. In one prospectively followed
cohort, treatment until tumor size is b1 cm (for macroadenomas) and
until women had at least 3 normalmenstrual periodswas not associated
with complications during pregnancy [4]. Dopamine agonists generally
are discontinued when pregnancy is conﬁrmed [2]. Transsphenoidal re-
section of the tumormaybe considered formacroprolactinomas that are
resistant to dopamine agonists or are in proximity to or encroaching the
optic chiasm because these tumors may enlarge during pregnancy and
compromise vision. The risks of surgery must also be considered with
regard to impairment of pituitary function and fertility. Fig. 2 illustrates
the decision-making process during the management of prolactinomas
in women taking into consideration desires for pregnancy, tumor size
and response to medical therapy.
3.2. What are the Risks During Pregnancy?
When considering treatment of prolactinomas during pregnancy as
in case 1, several concerns must be addressed: the potential effects of
various therapies on the fetus and the risks of tumor growth and
tumor-related complications in the mother.
The pituitary gland normally increases in size during pregnancy [5].
Lactotroph hyperplasia caused by elevated estrogen levels is thought to
be the cause for the pituitary enlargement [6]. Growth of prolactinomas
(2–8 mm) has also been reported during pregnancy [7], and the risk ofFig. 2. Treatment approaches for reproductive-aged women with prolactintumor growth appears to be higher in macroadenomas (22.9%) com-
pared with microadenomas (2.7%) [3].
3.3. What is the Risk of Apoplexy and Hemorrhage in Pregnancy? Does a
History of Pituitary Apoplexy in Prior Pregnancy Change Management
Considerations During a Subsequent Pregnancy?
Pituitary apoplexy is a rare complication of prolactinomas (preva-
lence, 0.08%) [8]. Hemorrhage within a prolactinoma during pregnancy
is exceedingly rare, with 5 cases reported in macroadenomas and 2 in
microadenomas [9,10]. Given the paucity of cases of pituitary apoplexy
during pregnancy, most data are from case series of nonpregnant pa-
tients. Patients with prolactinoma and apoplexy usually develop apo-
plexy within 1 week to 12 months after initiation of dopamine
agonists [10]. No data are available about the risk of recurrent apoplexy
and likely reﬂects the very low risk of a recurrent event.Without data to
guide who would beneﬁt from continuing dopamine agonists during
pregnancy, practice varies. Dopamine agonists might be continued or
restarted during pregnancy for macroprolactinomas with suprasellar
extension, especially if the patient has mass effect symptoms [2].
3.4. What are the Potential Harmful Effects to the Fetus When Dopamine
Agonists are Reinitiated or Continued During Pregnancy?
Data are limited on the safety of dopamine agonists after the ﬁrst tri-
mester. A total of 13 patients from case reports and small case series re-
ceived treatment with bromocriptine or cabergoline later in pregnancy
with no reported adverse outcomes to the fetus [3,7,11]. In Case 1, DA
therapy was reinitiated during the third trimester of pregnancy after
the patient developed pituitary apoplexy and MRI demonstrated en-
largement of the tumor. During her second pregnancy, because the
tumor had reduced in size on cabergoline, DA therapywas discontinued
once pregnancy was conﬁrmed without the development of complica-
tions. Even for the same patient, treatment considerations may change
in subsequent pregnancies depending on response to medical therapy.
3.5. When is Radiosurgery Considered in the Treatment of Prolactinomas?
Case 2 exempliﬁes use of an unconventional therapy for
prolactinomas. Stereotactic radiosurgery is not standard therapy for
prolactinomas, but it can be considered in the following scenarios:omas. DA indicates dopamine agonist; TSS, transsphenoidal surgery.
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transsphenoidal surgery is unlikely to provide signiﬁcant beneﬁt
(e.g., tumors with extensive cavernous sinus extension); and 2) tumor
is unresponsive to medical therapy and transsphenoidal surgery. For
the reproductive-age woman desiring to maintain fertility, tumor loca-
tion is important when assessing the risk of pituitary dysfunction after
transsphenoidal surgery or stereotactic radiosurgery. For patient 2, the
location of the tumor primarily in the left cavernous sinus made
transsphenoidal surgery less likely to result in a cure but decreased
her risk of pituitary injury from stereotactic radiosurgery. However,
for patient 1, radiosurgery was not considered. She had tolerated DA
therapy, and the location of the tumor within the sella increased
the risk of pituitary injury from radiosurgery potentially causing
hypogonadotropic hypogonadism and impairing fertility. Moreover,
the effect of tumor shrinkage from radiosurgery may take years.
3.6. What are the Expected Beneﬁts and Risks of Radiosurgery?
Rates of biochemical remission after radiosurgery (deﬁned as nor-
malization of prolactin levels without dopamine agonists) range from
18% to 46% [12,13]. In patients who did not achieve biochemical remis-
sion, an additional 46%had clinical improvement, with orwithout dopa-
mine agonists (14% vs 32%, respectively) [12]. The most common and
clinically important adverse effect is pituitary dysfunction,which occurs
in 15% to 42% of cases [12,14], and would be of particular importance in
terms of fertility and additional risks during pregnancy for the
reproductive-age woman. To our knowledge, no rates of pregnancy
after radiosurgery for prolactinomas have been published. Here, we re-
port the ﬁrst case of a successful pregnancy without pituitary dysfunc-
tion or complications 3 years after radiosurgery for prolactinoma.
4. Conclusion
In this report, we present cases that illustrate individualized ap-
proaches to the treatment of macroprolactinomas in reproductive-
aged women. Management of macroprolactinomas in women desiring
pregnancy requires careful consideration of alternatives to surgerywhich could impair pituitary function and fertility and awareness of
treatment goals that can minimize the risks for pituitary apoplexy and
vision loss during pregnancy. It is important to increase awareness of
these options prior to initiation of treatment and conception.
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